Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 8/20 | 1.00 |
| ▸ | HTR3A | P46098 | 1/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 1/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 1/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14479461 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3ACHRNB4CHRNA3CHRNB2 | |
| SCHEMBL29422976 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3ACHRNB4CHRNA3CHRNB2 | |
| SCHEMBL29366074 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3ACHRNB4CHRNA3CHRNB2 | |
| SCHEMBL18016312 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3ACHRNB4CHRNA3CHRNB2 | |
| Hydrochloric Acid SCHEMBL6322692 | 0.98 | CHRNA7 (0.97) | CHRNA7HTR3ACHRNB4CHRNA3CHRNB2 | |
| Hydrochloric Acid SCHEMBL1790893 | 0.98 | CHRNA7 (0.97) | CHRNA7HTR3ACHRNB4CHRNA3CHRNB2 | |
| SCHEMBL928208 | 0.90 | CHRNA7 (0.82) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| Fumaric Acid SCHEMBL15663041 | 0.90 | CHRNA7 (0.81) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| Fumaric Acid SCHEMBL15663039 | 0.90 | CHRNA7 (0.81) | CHRNA7HTR3ACHRNB4CHRNA3 | |
| SCHEMBL930430 | 0.87 | CHRNA7 (0.76) | CHRNA7HTR3ACHRNB4CHRNA3CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210145818-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | Poviva Corp. | 2021-05-20 | — | — | US | claimed |
| EP-3781163-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-02-24 | — | — | EP | claimed |
| EP-3284467-B1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA INC (US) | 2019-10-30 | — | — | EP | claimed |
| WO-2019202396-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | POVIVA TEA, LLC (US) | 2019-10-24 | — | — | WO | claimed |
| EP-3328383-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | Attenua, Inc. (US) | 2018-06-06 | — | — | EP | claimed |
| US-9937168-B2 | Nicotine-containing pharmaceutical compositions | NICONOVUM USA, INC. (US) | 2018-04-10 | — | — | US | claimed |
| EP-3284467-A1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | Niconovum USA, Inc. (US) | 2018-02-21 | — | — | EP | claimed |
| EP-2566476-B1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA INC (US) | 2017-11-22 | — | — | EP | claimed |
| US-20170326138-A1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA, INC. (US) | 2017-11-16 | — | — | US | claimed |
| US-20170273957-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | ATTENUA, INC. | 2017-09-28 | — | — | US | claimed |
| US-20110274628-A1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA, INC. | 2011-11-10 | — | — | US | claimed |
| WO-2011139811-A1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS | NICONOVUM USA, INC. (US) | 2011-11-10 | — | — | WO | claimed |
| EP-2316836-A1 | Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors | Abbott Laboratories (US) | 2011-05-04 | — | — | EP | claimed |
| US-7399765-B2 | Substituted diazabicycloalkane derivatives | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | claimed |
| CN-101189233-A | Substituted diazabicycloalkane derivatives as ligands for the alpha 7 nicotinic acetylcholine receptor | ABBOTT LAB (US) | 2008-05-28 | — | — | CN | claimed |
| JP-2007521323-A | — | — | 2007-08-02 | — | — | JP | claimed |
| EP-1664045-A1 | SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | Abbott Laboratories (US) | 2006-06-07 | — | — | EP | claimed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | claimed |
| WO-2005028477-A1 | SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETY LCHOLINE RECEPTORS | ABBOTT LABORATORIES (US) | 2005-03-31 | — | — | WO | claimed |
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | ABBOTT LABORATORIES | 2005-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273957-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | CHRNA7, CHRNA1, CHRNG | CHRNA7 1/4885HTR3A 157/4885CHRNB4 15/4885 |
| US-20210145818-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | CHRNA5, SLC18A3, CHRNA6 | CHRNA7 12/4885HTR3A 287/4885CHRNB4 11/4885 |
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | CHRNA7, CHRNA1, CHRNA5 | CHRNA7 1/4885HTR3A 160/4885CHRNB4 25/4885 |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | CHRNA7, CHRNA2, CHRNA6 | CHRNA7 1/4885HTR3A 38/4885CHRNB4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.